Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
Decided June 4, 2026. Ketanji Brown Jackson delivered the opinion of the Court.
Docket 24-889 · 608 U.S. ___ (2026)
Holding
Amarin has failed to state a claim for actively inducing infringement of its brand-name drug’s patented uses in violation of 35 U. S. C. §271(b), so its complaint cannot withstand Hikma’s motion to dismiss.
The Court’s statement of the holding, from the opinion’s syllabus. The syllabus is prepared by the Reporter of Decisions and is not part of the opinion of the Court. Read the official opinion for authority.
How the Justices voted
Decided 9–0.
Majority · 9
“Concurring” means agreeing with the outcome; any split shown is the Court’s judgment, not each Justice’s reasoning. The lineup is the syllabus’s disposition of who wrote and joined each opinion. Source: the opinion’s syllabus (supremecourt.gov).
Official text
Read the official opinion (PDF, supremecourt.gov)
Explore from here
Ketanji Brown Jackson’s profile · All Supreme Court opinions · The Supreme Court
Source: Supreme Court of the United States, slip opinions (2026). Data last verified 2026-08-15. Informational only; verify against the primary source before relying. Not a consumer report (FCRA).